Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02999854 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
A Phase 3 study, sponsored by Kiadis Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
NCT02999854 is a Phase 3 study that was terminated before completion, run by Kiadis Pharma. The registered enrollment target is 63 participants.
The verdict
NCT02999854, a Phase 3 study, was terminated before completion, sponsored by Kiadis Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration of high dose cyclophosphamide (PTCy) in patients with a hematologic malignancy. An additional objective of the study is to compare the effect of the two treatments on quality of life.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL ATIR101
- PROCEDURE T-cell depleted HSCT from a related, haploidentical donor
- PROCEDURE T-cell replete HSCT from a related, haploidentical donor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-11-29 |
| Est. Completion | 2021-12-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02999854
The ClinicalTrials.gov registry entry for NCT02999854 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kiadis Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02999854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02999854 about?
NCT02999854 is a clinical study titled "Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer". The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration of high dose cyclophosphamide (PTCy) in patients with a hematologic mal...
What is the current status of trial NCT02999854?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2017-11-29. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT02999854?
The interventions under investigation include: Cyclophosphamide (DRUG), ATIR101 (BIOLOGICAL), T-cell depleted HSCT from a related, haploidentical donor (PROCEDURE), T-cell replete HSCT from a related, haploidentical donor (PROCEDURE).
Who is sponsoring clinical trial NCT02999854?
This trial is sponsored by Kiadis Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.